Carcinogenesis Advance Access originally published online on March 28, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis, Vol. 24, No. 5, 945-952,
May 2003
© 2003 Oxford University Press
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION |
Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice
1 The University of Texas M.D.Anderson Cancer Center, Science Park-Research Division, PO Box 389, Park Road 1C, Smithville, TX 78957, USA
2 Division of Cancer Prevention and Control, National Institutes of Health, Bethesda, MD 20852, USA
3 To whom correspondence should be addressed Email: sa83161{at}odin.mdacc.tmc.edu
The cyclooxygenase-2 (COX-2) inhibitor celecoxib and the ornithine decarboxylase (ODC) inhibitor difluoromethylornithine (DFMO) were each previously shown to prevent skin tumor development when administered throughout the course of UV irradiation. This raised the question of whether maintenance or continued growth of existing tumors required prostaglandins, the product of COX, or polyamines, the product of ODC. To address this question, SKH hairless mice were irradiated 3 times/week with 90 mJ/cm2; this dose was increased 10% weekly to a maximum of 175 mJ/cm2. UV was stopped at 27 weeks, at which time there were an average of 5 papillomas/mouse. The mice were then placed in one of four treatment groups: group 1, no treatment; group 2, 0.4% DFMO in the drinking water; group 3, 500 p.p.m. celecoxib in the diet (AIN76); group 4, both DFMO and celecoxib. The control group continued to produce new tumors in a nearly linear manner such that by week 31 the tumor number had nearly doubled, i.e. 
10 tumors/mouse. The group receiving DFMO showed significant tumor regression, losing an average of 1 tumor/mouse/week, such that 50% of the tumors remained at week 31. The celecoxib group showed a 25% reduction in tumor number. The group receiving the combination of celecoxib and DFMO showed the greatest regression, with an 89% reduction in tumor number compared with the control group. There was also a corresponding reduction in the size of the tumors. To determine whether tumor regression was permanent or required continued treatment, all treatments were stopped at 31 weeks. Over the next 4 weeks, tumors reappeared at the same rate in all treatment groups. It is concluded that the combination of celecoxib and DFMO are potent therapeutic agents for skin cancer, although the benefits are lost with the cessation of treatment.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Zattra, C. Coleman, S. Arad, E. Helms, D. Levine, E. Bord, A. Guillaume, M. El-Hajahmad, E. Zwart, H. van Steeg, et al. Polypodium leucotomos Extract Decreases UV-Induced Cox-2 Expression and Inflammation, Enhances DNA Repair, and Decreases Mutagenesis in Hairless Mice Am. J. Pathol., November 1, 2009; 175(5): 1952 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Thomas-Ahner, B. C. Wulff, K. L. Tober, D. F. Kusewitt, J. A. Riggenbach, and T. M. Oberyszyn Gender Differences in UVB-Induced Skin Carcinogenesis, Inflammation, and DNA Damage Cancer Res., April 1, 2007; 67(7): 3468 - 3474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Tong, R. T. Van Dross, A. Abu-Yousif, A. R. Morrison, and J. C. Pelling Apigenin Prevents UVB-Induced Cyclooxygenase 2 Expression: Coupled mRNA Stabilization and Translational Inhibition Mol. Cell. Biol., January 1, 2007; 27(1): 283 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kim, K.S. Prabhu, F. J. Gonzalez, and J. M. Peters Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-{beta}/{delta} (PPAR{beta}/{delta}) Carcinogenesis, May 1, 2006; 27(5): 1105 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. He, Y. M. Sung, J. DiGiovanni, and S. M. Fischer Thiazolidinediones Inhibit Insulin-Like Growth Factor-I-Induced Activation of p70S6 Kinase and Suppress Insulin-Like Growth Factor-I Tumor-Promoting Activity Cancer Res., February 1, 2006; 66(3): 1873 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Millan, D. Rico, H. Peinado, N. Zarich, K. Stamatakis, D. Perez-Sala, J. M. Rojas, A. Cano, and L. Bosca Potentiation of tumor formation by topical administration of 15-deoxy-{Delta}12,14-prostaglandin J2 in a model of skin carcinogenesis Carcinogenesis, February 1, 2006; 27(2): 328 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Marwaha, Y.-H. Chen, E. Helms, S. Arad, H. Inoue, E. Bord, R. Kishore, R. D. Sarkissian, B. A. Gilchrest, and D. A. Goukassian T-oligo Treatment Decreases Constitutive and UVB-induced COX-2 Levels through p53- and NF{kappa}B-dependent Repression of the COX-2 Promoter J. Biol. Chem., September 16, 2005; 280(37): 32379 - 32388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Brown and R. N. DuBois COX-2: A Molecular Target for Colorectal Cancer Prevention J. Clin. Oncol., April 20, 2005; 23(12): 2840 - 2855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Lubet, K. Huebner, L. Y.Y. Fong, D. C. Altieri, V. E. Steele, L. Kopelovich, C. Kavanaugh, M.M. Juliana, S.-j. Soong, and C. J. Grubbs 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin Carcinogenesis, March 1, 2005; 26(3): 571 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pereira, L. Tao, W. Wang, Y. Li, A. Umar, V. E. Steele, and R. A. Lubet Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-{alpha} gene in rat colon tumors Carcinogenesis, October 1, 2004; 25(10): 1917 - 1923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-S. Chun, S.-H. Kim, Y.-S. Song, and Y.-J. Surh Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin Carcinogenesis, May 1, 2004; 25(5): 713 - 722. [Abstract] [Full Text] [PDF]
|
|